Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL

NCT01880567 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01880567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01880567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Ibrutinib Plus Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma or Elderly Patients With Newly Diagnosed MCL
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 15, 2013
Completion date
July 31, 2028
Enrollment
113 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ccnd1 positive, ccnd2 positive, ccnd3 positive, cd20 positive, mantle cell lymphoma, recurrent mantle cell lymphoma, refractory mantle cell lymphoma